FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1770-1771 October 30, 2003 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lalezari, J. P. Related Article by Lazzarin, A. PubMed Citation

To the Editor: In the T-20 vs. Optimized Regimen Only Study 1 (TORO 1), reported by Lalezari et al. (May 29 issue),¹ enfuvirtide, when added to an optimized salvage antiretroviral regimen, increased by 12 percent the proportion of patients who had undetectable plasma human immunodeficiency virus type 1 (HIV-1) RNA levels at week 24. Ninety-five percent adherence to antiretroviral therapy is key for sustained treatment success; adherence, or the lack thereof, is largely driven by toxic effects.^2,3,4 Enfuvirtide caused injection-site reactions in 98 percent of the patients, although only 3 percent discontinued therapy as a result. Adherence to enfuvirtide therapy . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.